Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)

CAPS Rating: 1 out of 5

A development stage company focuses on the discovery and development of oncolytic viruses for the treatment of cancers.

Recs

0
Player Avatar ryebakerboy (< 20) Submitted: 8/8/2012 10:40:39 AM : Outperform Start Price: $2.86 ONCY Score: -24.24

I believe the PHIII trial has a high likelihood of success, in which case the stock will take off given the high number of cancer indications reosylin is applicable to

Report this Post Reply

Featured Broker Partners


Advertisement